Author

Akata Abung

Observed names: A Abung, A. Abung, AKATA ABUNG, Abung, Akata

Observed institutions: Loyola University Medical Center, Enugu State University of Science and Technology, Loyola University Chicago, Worcestershire Acute Hospitals NHS Trust, Latin American School of Medicine, University of Calabar, General Hospital Lagos, Odan, Near East University, American University of Antigua

OpenAlex ID: A5038158569

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

PDF

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

PDF

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

PDF

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

PDF

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

Diabetic Ketoacidosis Complicated by Thrombotic Thrombocytopenic Purpura: A Rare Association

2023 · Chinanu I Nwankwo, Kemar A Samuels, et al. · Cureus · 2

PDF

Calprotectin as Biomarker in Cardiovascular Disease: A Systematic Review

2023 · Maryam Iqbal, Chisom Euphemia Alakwe-Ojimba, et al. · Journal of Advances in Medicine and Medical Research · 1

PDF

Zavegepant Nasal Spray for Treatment of Acute Migraine: A Systematic Review

2023 · Victor Ameh Odoma, Daniel Nwabueze, et al. · Journal of Advances in Medicine and Medical Research · 1

PDF

Metastatic Breast Cancer Presenting With Ground Glass Infiltrates and Acute Respiratory Failure

2025 · NOOR UL AIN ALVI, FNU HARSHA, et al. · CHEST Journal

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

PDF

The Efficacy of AI-Assisted CADe Systems in Colorectal Polyps and Adenomas during Colonoscopies: A Systematic Review

2023 · Stella Nwosu, Norense Ehimwenma, et al. · Journal of Advances in Medicine and Medical Research

PDF

Works count: 17

Citation count: 2,239

H-index: 9

I10-index: 9